News
British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...
With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...
1don MSN
UnitedHealth Group CEO Andrew Witty is stepping down from his post for personal reasons and the healthcare giant says it’s ...
Discover the details about Andrew Witty’s life, such as his educational qualifications, career graph, major achievements, ...
4h
Capital Market on MSNGSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/shareProfit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses ...
Quarterly Net Profit at Rs. 262.87 crore in March 2025 up 35.17% from Rs. 194.48 crore in March 2024. EBITDA stands at Rs. 373.87 crore in March 2025 up 30.23% from Rs. 287.09 crore in March 2024.
Explore more
In 2024, GlaxoSmithKline withdrew Flovent from the market. The inhaler was commonly prescribed to prevent asthma attacks in children. The pharma company continued to sell a chemically identical ...
Witty will act as a senior advisor to his successor, Stephen Hemsley, who served as UnitedHealth Group’s CEO from 2006 to ...
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...
An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...
GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results